Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S329-S335

  Hill Batorski, Lindsay ^a   Halfmann, Peter ^a   Marzi, Andrea ^b   Lopes, Tiago J S ^a,c   Neumann, Gabriele ^a   Feldmann, Heinz ^b   Kawaoka, Yoshihiro ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c THE UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Ebola virus; IL 1Ra; Il1rn; interleukin 1 receptor antagonist

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; CYTOKINE; IL1RN PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; EBOLA HEMORRHAGIC FEVER; FEMALE; INFECTION SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL RATE; VIRAL CLEARANCE; WEIGHT REDUCTION; AFRICA; ANIMAL; C57BL MOUSE; DISEASE PREDISPOSITION; EBOLAVIRUS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOGENICITY; T LYMPHOCYTE; VIROLOGY;

AFRICA, WESTERN; ANIMALS; CYTOKINES; DISEASE SUSCEPTIBILITY; EBOLAVIRUS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMORRHAGIC FEVER, EBOLA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES;

EID: 84943232181     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv335     Document Type: Article

References (48)

1. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5:423-6.
2. Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003; 77:9733-7.
3. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
4. Centers for Disease Control and Prevention. Outbreaks chronology: ebola hemorrhagic fever. 2015. http://www.cdc.gov/vhf/ebola/resources/ outbreak-table.html. Accessed 3 June 2015.
5. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128:163-8.
6. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355:2210-5.
7. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001; 124:453-60.
8. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010; 4:e837.
9. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014; 210:558-66.
10. Ebihara H, Rockx B, Marzi A, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 2011; 204(suppl 3):S991-9.
11. Cilloniz C, Ebihara H, Ni C, et al. Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol 2011; 85:9060-8.
12. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-37.
13. Reiner AP, Wurfel MM, Lange LA, et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol 2008; 28:1407-12.
14. Lind H, Zienolddiny S, Ryberg D, et al. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer 2005; 50:285-90.
15. Fragoso JM, Delgadillo H, Llorente L, et al. Interleukin 1 receptor antagonist polymorphisms are associated with the risk of developing acute coronary syndrome in Mexicans. Immunol Lett 2010; 133:106-11.
16. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
17. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999; 179(suppl 1):S248-58.
18. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(suppl 1): S203-17.
19. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2:e73.
20. Ebihara H, Zivcec M, Gardner D, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013; 207:306-18.
21. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1-24.
22. Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001; 125:233-42.
23. van der Groen G, JacobW, Pattyn SR. Ebola virus virulence for newborn mice. J Med Virol 1979; 4:239-40.
24. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011; 204(suppl 3):S986-90.
25. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338:1423-4.
26. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99:2930-40.
27. Thea DM, Porat R, Nagimbi K, et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med 1996; 124:757-62.
28. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 1997; 109:54-8.
29. de-Oliveira-Pinto LM, Gandini M, Freitas LP, et al. Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1beta and CCL2/MCP-1 in dengue fever and parvovirosis.Mem Inst Oswaldo Cruz 2012; 107:48-56.
30. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-6.
31. Meyer NJ, Ferguson JF, Feng R, et al. A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med 2014; 190:656-64.
32. Endo S, Inada K, Yamada Y, et al. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns. J Med 1996; 27:57-71.
33. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 1996; 93:11008-13.
34. Kafka D, Ling E, Feldman G, et al. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int Immunol 2008; 20:1139-46.
35. Rider P, Carmi Y, Guttman O, et al. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187:4835-43.
36. Miller LS, Pietras EM, Uricchio LH, et al. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol 2007; 179:6933-42.
37. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-46.
38. Basu S, Hodgson G, Katz M, Dunn AR. Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood 2002; 100:854-61.
39. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-27.
40. Sergejeva S, Ivanov S, Lotvall J, Linden A. Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol 2005; 33:248-53.
41. Pan ZZ, Parkyn L, Ray A, Ray P. Inducible lung-specific expression of RANTES: preferential recruitment of neutrophils. Am J Physiol Lung Cell Mol Physiol 2000; 279:L658-66.
42. Fisher-Hoch SP, Platt GS, Neild GH, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152:887-94.
43. Fisher-Hoch SP, Platt GS, Lloyd G, et al. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 1983; 2:1055-8.
44. Formenty P, Hatz C, Le Guenno B, et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999; 179(suppl 1):S48-53.
45. Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78:10370-7.
46. Lehr HA, Arfors KE. Mechanisms of tissue damage by leukocytes. Curr Opin Hematol 1994; 1:92-9.
47. Ginsburg I, Kohen R. Cell damage in inflammatory and infectious sites might involve a coordinated "cross-talk" among oxidants, microbial haemolysins and ampiphiles, cationic proteins, phospholipases, fatty acids, proteinases and cytokines (an overview). Free Radic Res 1995; 22:489-517.
48. Silva MT, do Vale A, dos Santos NM. Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis 2008; 13:463-82.